As of 2024-12-14, the EV/EBITDA ratio of Jounce Therapeutics Inc (JNCE) is 1.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. JNCE's latest enterprise value is -51.62 mil USD. JNCE's TTM EBITDA according to its financial statements is -48.70 mil USD. Dividing these 2 quantities gives us the above JNCE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 16.5x | 14.8x |
| Forward P/E multiples | 13.9x - 19.3x | 15.2x |
| Fair Price | (10.02) - (12.40) | (11.06) |
| Upside | -632.9% - -759.8% | -688.5% |
| Date | EV/EBITDA |